Marina Biotech, Inc. - Product Pipeline Review - 2015

Date: July 29, 2015
Pages: 32
Price:
US$ 1,500.00 US$ 1,200.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M058A83A17EEN
Leaflet:

Download PDF Leaflet

Marina Biotech, Inc. - Product Pipeline Review - 2015

SUMMARY

Global Markets Direct’s, ‘Marina Biotech, Inc. - Product Pipeline Review - 2015’, provides an overview of the Marina Biotech, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Marina Biotech, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides brief overview of Marina Biotech, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Marina Biotech, Inc.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Marina Biotech, Inc.’s pipeline products
REASONS TO BUY
  • Evaluate Marina Biotech, Inc.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Marina Biotech, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Marina Biotech, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Marina Biotech, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Marina Biotech, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Marina Biotech, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Marina Biotech, Inc. Snapshot
Marina Biotech, Inc. Overview
Key Information
Key Facts
Marina Biotech, Inc. - Research and Development Overview
Key Therapeutic Areas
Marina Biotech, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Marina Biotech, Inc. - Pipeline Products Glance
Marina Biotech, Inc. - Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Marina Biotech, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Marina Biotech, Inc. - Drug Profiles
CEQ-508
Product Description
Mechanism of Action
R&D Progress
CEQ-501
Product Description
Mechanism of Action
R&D Progress
MDR-09521
Product Description
Mechanism of Action
R&D Progress
RNAi Oligonucleotide to Inhibit MicroRNA-122 for Oncology
Product Description
Mechanism of Action
R&D Progress
RNAi Oligonucleotides for Duchenne Muscular Dystrophy
Product Description
Mechanism of Action
R&D Progress
RNAi Oligonucleotides for Myotonic Dystrophy
Product Description
Mechanism of Action
R&D Progress
RNAi Oligonucleotides to Inhibit PLK1 for Malignant Ascites
Product Description
Mechanism of Action
R&D Progress
Marina Biotech, Inc. - Pipeline Analysis
Marina Biotech, Inc. - Pipeline Products by Target
Marina Biotech, Inc. - Pipeline Products by Route of Administration
Marina Biotech, Inc. - Pipeline Products by Molecule Type
Marina Biotech, Inc. - Pipeline Products by Mechanism of Action
Marina Biotech, Inc. - Recent Pipeline Updates
Marina Biotech, Inc. - Dormant Projects
Marina Biotech, Inc. - Company Statement
Marina Biotech, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Marina Biotech, Inc., Key Information
Marina Biotech, Inc., Key Facts
Marina Biotech, Inc. - Pipeline by Indication, 2015
Marina Biotech, Inc. - Pipeline by Stage of Development, 2015
Marina Biotech, Inc. - Monotherapy Products in Pipeline, 2015
Marina Biotech, Inc. - Partnered Products in Pipeline, 2015
Marina Biotech, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
Marina Biotech, Inc. - Phase I, 2015
Marina Biotech, Inc. - Preclinical, 2015
Marina Biotech, Inc. - Pipeline by Target, 2015
Marina Biotech, Inc. - Pipeline by Route of Administration, 2015
Marina Biotech, Inc. - Pipeline by Molecule Type, 2015
Marina Biotech, Inc. - Pipeline Products by Mechanism of Action, 2015
Marina Biotech, Inc. - Recent Pipeline Updates, 2015
Marina Biotech, Inc. - Dormant Developmental Projects,2015
Marina Biotech, Inc., Subsidiaries

LIST OF FIGURES

Marina Biotech, Inc. - Pipeline by Top 10 Indication, 2015
Marina Biotech, Inc. - Pipeline by Stage of Development, 2015
Marina Biotech, Inc. - Monotherapy Products in Pipeline, 2015
Marina Biotech, Inc. - Partnered Products in Pipeline, 2015
Marina Biotech, Inc. - Pipeline by Top 10 Target, 2015
Marina Biotech, Inc. - Pipeline by Top 10 Route of Administration, 2015
Marina Biotech, Inc. - Pipeline by Top 10 Molecule Type, 2015
Marina Biotech, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Skip to top


Hawaii Biotech, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Sep, 2015 · 24 pages
Longevity Biotech, Inc - Product Pipeline Review - 2015 US$ 1,200.00 Feb, 2015 · 29 pages
JHL Biotech, Inc. - Product Pipeline Review - 2015 US$ 1,275.00 Dec, 2015 · 25 pages
Osel Inc. - Product Pipeline Review - 2014 US$ 1,125.00 Jul, 2014 · 20 pages

Ask Your Question

Marina Biotech, Inc. - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: